UroGen develops and sells gel-based treatments for urinary tract cancers, including Jelmyto and Zusduri. It last closed at $29.87 on Nov 17, up 6.30% on the day. In the past 30 days there were 1 dark pool print totaling $703K, the largest $703K.
Only 1 firm rated URGN in the past 90 days, not enough for a consensus
Average 12-month target
$56.00
▲ 87.5% upside
Based on 1 analyst who set a price target on URGN in the past 90 days. The average target is $56.00, with a high of $56.00 and a low of $56.00, compared with the last close of $29.87.
Low $56.00Avg $56.00High $56.00
Blue marker: last close $29.87
Highest target$56.00
Average target$56.00
Lowest target$56.00
Latest rating changes
GuggenheimMaintained
Nov 5Buy$56
GuggenheimMaintained
Aug 6Buy$58
HC Wainwright & Co.Maintained
Aug 6Buy$75
TD CowenMaintained
Aug 5Buy$60
GuggenheimMaintained
Jul 21Buy$42
Date
Firm
Action
Rating
Price target
Nov 5
Guggenheim
Maintained
Buy
$56
Aug 6
Guggenheim
Maintained
Buy
$58
Aug 6
HC Wainwright & Co.
Maintained
Buy
$75
Aug 5
TD Cowen
Maintained
Buy
$60
Jul 21
Guggenheim
Maintained
Buy
$42
Loading…
Technical Analysis
URGN · as of the Nov 17 close · updated after every close
Pullback inside a longer uptrend
The stock is 2% below its 20 day and 22% below its 50 day average. It is 6% below its 200 day average, so the longer trend is down. Momentum is neutral (RSI 44). The nearest support is the Pivot at $28.95, and the nearest resistance the 20 day average at $30.46.
Short trendBearish
Long trendBullish
MomentumNeutral
StretchNormal
VolatilityHigh, 7.9%/day
Key levels
$50.8152 week high+70.1%
$39.62100 day average+32.6%
$36.4050 day average+21.9%
$31.78200 day average+6.4%
$30.82Pivot R1+3.2%
$30.69Swing high (May 27)+2.7%
$30.4620 day average+2.0%
$29.87Last close
$28.95Pivot−3.1%
$28.00Pivot S1−6.3%
$26.00Swing low (Jun 1)−13.0%
$16.5052 week low−44.8%
Indicators
RSI (14)
44.49
Middle of its range
Neutral
MACD
-2.79
Above its signal line
Bullish
Stochastic
38.4
Middle of its range
Neutral
ADX (14)
41.5
Strong downtrend
Williams %R
-43.3
Oversold below −80, overbought above −20
Neutral
CCI (20)
-27.2
Oversold below −100, overbought above 100
Neutral
Rate of change
−13.2%
Change over 10 sessions
Bearish
ATR (14)
$2.35
Typical daily range, 7.8% of price
MA 10Above
MA 20Below
MA 50Below
MA 100Below
MA 200Below
Falling
Short trendBearish
Long trendNot enough history
MomentumWeak
StretchNormal
VolatilityNormal, 15.9%/day
Key levels
$50.8152 week high+70.1%
$39.62100 day average+32.6%
$36.4050 day average+21.9%
$31.78200 day average+6.4%
$30.82Pivot R1+3.2%
$30.69Swing high (May 27)+2.7%
$30.4620 day average+2.0%
$29.87Last close
$28.95Pivot−3.1%
$28.00Pivot S1−6.3%
$26.00Swing low (Jun 1)−13.0%
$16.5052 week low−44.8%
Indicators
RSI (14)
43.03
Middle of its range
Neutral
MACD
-0.51
Below its signal line
Bearish
Stochastic
10.8
Near the bottom of its range
Oversold
ADX (14)
34.4
Trending down
Williams %R
-75.8
Oversold below −80, overbought above −20
Neutral
CCI (20)
-152.0
Oversold below −100, overbought above 100
Oversold
Rate of change
−29.4%
Change over 10 sessions
Bearish
ATR (14)
$4.74
Typical daily range, 15.9% of price
MA 10Below
MA 20Below
MA 50Above
MA 100Above
MA 200–
What happened before, for URGN
Signal name goes hereSince a recent date
9 times
+0.0%
Signal name goes hereSince a recent date
9 times
+0.0%
Signal name goes hereSince a recent date
9 times
+0.0%
What happened before
See how URGN did after each of today's signals in the past: how often it was higher 10 sessions later, and the typical move, next to its usual record.
November seasonalityHow URGN usually does this month. See Seasonality
Calculated from daily prices after each close. Signals describe the chart, not where the stock will go. Past patterns often fail. Not investment advice.
Seasonality
How URGN has done in each calendar month: the average and median return, how often each month finished higher, and every year since 2017.
From SEC Form 13F filings for Sep 30, 2026. What the filings show, not a forecast: positions can be up to 45 days old and leave out short sales.
AI Auto Pilots
Paper trading
StreetAlpha runs four autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether URGN is in one of them and how their past URGN trades turned out.
UroGen is a biotechnology company based in Ra'Anana, Israel, that develops and sells treatments for urothelial cancers, which affect the lining of the urinary tract. Its products use a gel technology called RTGel, which turns from liquid to gel at body temperature so that a cancer drug can stay in the bladder or upper urinary tract for longer. Its approved products, Jelmyto and Zusduri, both contain the chemotherapy drug mitomycin, and the company is also developing an investigational oncolytic virus. Its customers are patients with these cancers and the doctors who treat them.